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Tertiary lymphoid structures (TLS) are organized aggregates of lymphocytes, myeloid, 
and stromal cells that provide ectopic hubs for acquired immune responses. TLS share 
phenotypical and functional features with secondary lymphoid organs (SLO); however, 
they require persistent inflammatory signals to arise and are often observed at target 
sites of autoimmune disease, chronic infection, cancer, and organ transplantation. Over 
the past 10 years, important progress has been made in our understanding of the role of 
stromal fibroblasts in SLO development, organization, and function. A complex and ste-
reotyped series of events regulate fibroblast differentiation from embryonic life in SLOs to 
lymphoid organ architecture observed in adults. In contrast, TLS-associated fibroblasts 
differentiate from postnatal, locally activated mesenchyme, predominantly in settings of 
inflammation and persistent antigen presentation. Therefore, there are critical differences 
in the cellular and molecular requirements that regulate SLO versus TLS development 
that ultimately impact on stromal and hematopoietic cell function. These differences may 
contribute to the pathogenic nature of TLS in the context of chronic inflammation and 
malignant transformation and offer a window of opportunity for therapeutic interventions 
in TLS associated pathologies.
Keywords: tertiary lymphoid structures, chemokines, tumor necrosis factor-alpha, lymphotoxin alpha1, beta2 
heterotrimer, fibroblasts
iNTRODUCTiON
Organs are defined as collection of cells, extracellular structures, and fluids, joined into an operational 
unit to serve a common function. The anatomy of an organ is designed by its structural elements, 
or resident stromal cells, which provide shape and compartmentalization to the tissues. Secondary 
lymphoid organs (SLOs), which include spleen, lymph nodes (LN), and Peyer’s patches (PP), largely 
conform to this. SLOs hold a network of fibroblasts, vessels, and nerves that support a large mobile 
population of leukocyte and which support immune surveillance and response to noxious agents 
(1, 2). This elegant organization of SLOs develops in a highly conserved and regulated process that 
largely occurs, both in mice and humans, in embryonic and early postnatal life (3, 4). SLOs evolved 
simultaneously with the development of an adaptive immune system in vertebrates, with hundreds 
of LN being distributed at strategic sites, thereby providing a platform for immune cell clustering at 
well-defined areas. This enables rapid and more efficient adaptive immune responses that outpace 
pathogen replication, spread, and pathology (5).
Well-developed tertiary or ectopic lymphoid structures (TLS or ELS) resemble SLOs anatomi-
cally, as complex aggregates of leukocytes and specialized stromal cells. However, TLS are not 
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capsulated and lack an independent vascular network. TLS form 
within non-lymphoid tissue in response to specific pathogenic 
events (6–8) and are commonly found, in adult life, at sites of 
chronic inflammation and cancer (9–12). It is likely that the 
capacity to form TLS preceded the development of SLO during 
evolution, as a tool to accumulate innate immune cells at sites 
of inflammation in non-vertebrates and lower vertebrates, such 
as birds, amphibians, and reptiles (13, 14).
Mucosa-associated lymphoid tissues (MALT), such as 
cryptopatches (CP), fat-associated lymphoid clusters (FALC), 
and induced nasopharynx-associated lymphoid tissue (iNALT), 
may be placed, both anatomically and developmentally, between 
SLOs and TLSs. These are pre-programed in time and space, 
developing either pre- or postnatally at predetermined sites 
but are able to expand and accommodate specialized immune 
responses if required. In CPs, their development into IgA plasma 
cell-rich isolated lymphoid follicles (ILF) is a classic example of 
this phenomenon (5). Interestingly, ILF are reversible structures, 
as indicated by their disaggregation upon antibiotic treatment 
(15, 16). Similarly, TLS are considered reversible once the 
antigen source and inflammatory signals are cleared, as will be 
discussed later.
TLS anatomy is plastic and highly variable, as is its cellular 
composition. While a certain degree of T/B cell segregation, 
vascular specialization, and lymphoid tissue chemokine expres-
sion is often observed, the level of organization and formation 
of germinal centers (GC) is dependent on the context, stage, 
and site of the immune response. Unraveling the  mechanisms 
responsible for the differential maturation of the stromal and 
leukocyte compartments in TLS and the functional differences 
between SLO and TLS has provided key information on the 
biology, clinical relevance, and role of those structures as poten-
tial therapeutic targets. In this review, we discuss in detail the 
contribution of stromal cells, most notably fibroblasts, to both 
SLO and TLS development and function, and the potential to 
target therapeutically this specific cell type.
In a “resting state,” all organs of the body contain fibroblasts 
that provide structure and mechanical strength to the tissue. 
Fibroblast phenotype and function greatly differ between various 
anatomical sites, as shown by the extensive transcriptional dif-
ferences detected in fibroblasts isolated from different compart-
ments in diverse locations of the body (17). This specialization is 
further enhanced by the specific ability of fibroblasts to respond 
to a series of cytokines and inflammatory stimuli, which increase 
their proliferative capacity and induce functional adaptations to 
the environment (18–22). This review will focus on a subset of 
fibroblasts defined as “lymphoid tissue fibroblasts,” which inhabit 
SLOs and TLS, are characterized by extensive plasticity and 
specialized functions, and have recently emerged as important 
regulators of adaptive immunity (8, 23–25).
LYMPHOiD STROMAL CeLL 
DiFFeReNTiATiON iN SLOs AND TLS
In order to understand the TLS development, it is useful to 
review the development of LN and PP, which is initiated in the 
sterile environment of the embryo, at approximately E11 and E15, 
respectively. The locations at which LN develop are predetermined, 
at least in part, by endothelial expression of the lymphotoxin 
β receptor (LTβR) (26). Activation of the LTβR signaling pathway 
enables the clustering of CD45+CD4+CD3− hematopoietic lym-
phoid tissue inducer (LTi), also known as type 3 innate lymphoid 
cells (ILC3) expressing LTα1β2, TRANCE, and RORγt (3, 4).
The origin and identity of the signals that induce specifica-
tion of the mesenchymal progenitor cells prior to LTi arrival 
remain largely unknown. It is clear that a close anatomical and 
functional connection between immune cells, mesenchyme, and 
vascular structures is critical for the establishment of the anlage. 
At around E13.5, it is possible to identify the nascent LN anlage 
as small clusters of endothelial cells expressing both podoplanin 
(gp38) and ICAM-1. The anlage are surrounded by a layer of 
mesenchymal cells expressing PDGFRα, fibronectin, and ER-TR7 
and is separated from the outer layers of fibroblastic cells by a thin 
Perlecan+ basement membrane (27, 28). The early differentiation 
of the mesenchyme and the initial upregulation of ICAM-1 and 
VCAM-1, CXCL13 and IL-7, occurs at this stage in the absence of 
LTα1β2 or LTi cells and is thought to be regulated by retinoic acid 
signals released by neurons and/or ILC3 (29, 30). Nonetheless, 
LTα1β2 is required for the further upregulation of adhesion mol-
ecules and of lymphoid chemokines. LTα1β2 binds specifically to 
LTβR and activates the alternative pathway of the NF-κB cascade, 
while TNFα and LTα3 have TNFR1 and TNFR2 as main receptors 
and activate the canonical NF-κB pathway (1, 3). The combined 
activation of TNFR1- and LTβR-signaling pathways not only 
leads to the activation of both the classical and alternative NF-κB 
pathways, which act in synergy but also shows complex cross-
regulation. In addition, LTβR can be also activated by LIGHT 
(31). LTβ-receptor regulates in fibroblasts and endothelial cells 
the expression of various chemokines (CCL19/21, CXCL13) and 
survival factors (BAFF), while TNF receptor is required for the 
production of adhesion molecules, such as VCAM-1, ICAM-1, 
and MAdCAM (32–35). The activation of the alternative pathway, 
demonstrated by the expression of NIK and the transcription fac-
tor RelB, is a specific requirement for the activated mesenchyme 
to mature in a lymphoid tissue organizer cell (LTo) (1–3). Mature 
LTo specification facilitates, in turn, further attraction and reten-
tion of more LTi cells through the binding of CXCR5, CCR7, 
α4β1, α4β7, and LTα1β2 with their respective ligands (2, 3). These 
later steps coincide with the ingrowth of the mesenchymal layer 
into the endothelial bud (27, 28, 36, 37). The physical interaction 
between hematopoietic LTi and stromal LTo cells establishes a 
positive feedback loop that reinforces the formation of the cluster 
and leads to the stabilization of the anlagen with vascular dif-
ferentiation, development of high endothelial venules (HEVs), 
and eventually attraction and compartmentalization of mature 
lymphoid and myeloid cells (2–4).
Utilizing a CCL19-Cre dependent LTβR ablation (Ccl19-
Cre × Ltbrfl/fl mice), Ludewig and colleagues have recently shown 
that CCL19+ myofibroblastic stromal cell precursor cells can 
develop the basic LN infrastructure even in absence of LTβR 
triggering (38). Nonetheless, fibroblastic LTo cells require LTβR 
signaling to reach full maturation and immunological compe-
tence that includes strong expression of ICAM-1, VCAM-1, 
CCL19, CCL21, IL-7, and RANKL (28, 38, 39). Of note, LTo 
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responsible for the aggregation of different lymphoid tissues are 
not uniform. This is suggested by the observation that embryonic 
LTo cells in PP, mesenteric, and peripheral LN display transcrip-
tional differences as well as differential cellular and molecular 
requirements (40, 41).
Interestingly, LN development is associated with but not fully 
dependent on a functional lymphatic vasculature network. As a 
consequence, embryos lacking the major transcriptional regula-
tor for lymphatic cell development, Prox1, either due to full or 
conditional Prox1 deletion, fail to form mature LN. Both mutants 
develop hypoplastic LN anlagen containing small LTi clusters in 
areas of activated mesenchyme (42). Similarly, Clec-2 knockout 
mice, which exhibit a defect in lymphatic endothelial cell prolifera-
tion late in embryogenesis, form hypoplastic LNs with a mixture of 
blood and lymphatic flow and reduced LTi and LTo numbers (43).
Evolutionarily more ancient than LNs is the spleen that, 
together with gut-associated lymphoid tissue (GALT), represents 
the oldest SLO. The spleen is present in bony fish, amphibians, 
and reptiles, although in a less complex organization than that 
observed in mammals (14, 44). The development of the splenic 
white pulp cords that starts at birth in mice (45–48) and after 
15 weeks of gestation in humans (49) does not require LTi cells 
or LTα1β2 (14, 44, 50, 51). However, as observed in the LN, 
stromal cell maturation, chemokine expression, and lymphocyte 
compartmentalization still require LTα1β2 and TNFα (1, 3, 
52–56). Those ligands are likely to be provided by B cells and, 
as a consequence, B cell-deficient mice display smaller spleens, 
with poorly developed T zones (47). In conclusion, spleen and LN 
development depend on different types of inducer cells but show 
a similar hematopoietic–mesenchymal cell interaction, which 
eventually leads to a similar pathway of fibroblast maturation and 
lymphoid tissue compartmentalization.
Lymph nodes and PP anlagen formation in the embryo 
resemble a “sterile inflammation” (5, 13) aimed at forming organs 
before and independently from the encounter of danger signals. 
Thereby, these organs collate in a single, highly organized space 
antigen-presenting cells, naïve lymphocytes, and stromal cells 
that enable the rapid generation of adaptive immune responses 
against pathogens.
Tertiary lymphoid structures formation in the adult shares 
many similarities with SLO development; however, the order of 
events and molecular mechanisms responsible for TLS develop-
ment are significantly different from those regulating LN devel-
opment and partially different from those of the spleen. First, 
TLS form in the presence of lymphocytes that are absent during 
embryonic SLO formation. Second, TLS do not develop as separate 
encapsulated organs but arise as part of highly inflamed tissues, 
in response to a requirement for lymphocytes to cluster, survive, 
and generate local, efficient antigen-driven responses. Activation 
of the resident vascular structures including the upregulation of 
homing molecules to enable lymphocyte recruitment is therefore 
a prerequisite of TLS assembly (7, 8). However, while influenced 
by increased recruitment and defective lymphatic drainage of 
leukocytes, TLS formation is not simply determined by retention 
of activated cells in the tissue (57).
Modification of tissue-resident stromal cells into functional 
lymphoid tissue-like fibroblasts represents another hallmark 
feature of TLS, specifically, the ectopic and largely segregated 
expression of chemokines, such as CXCL13, CCL21, CCL19, 
and CXCL12, and of lymphocyte survival factors, such as IL-7, 
BAFF, and APRIL (7, 8). Once fully matured, TLS can display a 
specialized network of follicular dendritic cells (FDCs) capable 
of driving a functional GC response, and HEVs, differentiated 
from perivenular capillaries (57). Local upregulation of PNAd, 
MAdCAM, ICAM-1, and CCL21, first on flat, and later on high 
endothelial cells, enables the recirculation through the inflamed 
tissue of naïve T and B lymphocytes, previously excluded by the 
absence of cognate ligands for CCR7 and L-selectin (8, 57–59).
As opposed to SLO that arise on the backbone of a poorly 
differentiated mesenchyme, TLS form within organs whose 
mesenchyme is postnatal and specialized to support local 
anatomical and functional requirements (8). Accordingly, TLS 
assembly relies on a larger variety of mesenchymal organizer 
cells, hematopoietic inducer cells, and cytokines (6–8, 60). TLS 
preferentially arise in close proximity to vascular or epithelial 
ductal structures adjacent to pericytes, smooth muscle cells, or 
myofibroblast-like cells that share many functional and pheno-
typic features of LTo cells. For example, leukocyte aggregates in 
the synovium of patients with rheumatoid arthritis (RA) form in 
close proximity to networks of αSMA+ fibroblastic cells (61), and 
LTβR+ aortic smooth muscle cells have been observed in vascular 
TLS that form in murine models of atherosclerosis (62). Focal 
lymphocytic aggregations that define Sjogren’s syndrome (SS) 
assume a classical periductal structure in close contact to a layer 
of gp38+ myofibroblastic or pericytic cells that define the ductal 
basal membrane (63). Similarly, fibroblastic reticular stromal cells 
that share LTo and lymphoid tissue features have been identified 
in several murine and human TLS, including SS, primary biliary 
cirrhosis, insulitis, RA, and lungs infected by Pseudomonas 
aeruginosa (Table  1). More recently, a marked increase in the 
frequency of PDGFRα+PDGFRβ+Cadherin-11+ICAM-1+ fibro-
blasts has also been identified within cerebral lesions of mice that 
develop experimental autoimmune encephalomyelitis (EAE) 
(64). Recently, endothelial cells and perivascular fibroblasts of 
the brain were shown to nucleate local CD8+T cell responses to 
a neurotropic virus by expressing CCR7 ligands (65). As TLS-
associated LTo-like cells are considered resident and long-lived, 
in comparison to the circulating and short-lived hematopoietic 
cells, they may hold the key to the reversibility of TLS assembly, 
providing an interesting therapeutic target for this process.
PRiMiNG OF FiBROBLASTiC STROMAL 
CeLLS AT SiTeS OF iNFLAMMATiON
The cellular and molecular requirement for mesenchymal cell 
priming, leading to cell differentiation and specialization during 
TLS establishment, is debated. Transgenic expression of lymphoid 
tissue chemokines such as CCL21 and CXCL13 overcomes the 
requirement for LTi cells, but not of LTα1β2 in non– spontaneous 
models of TLS that form in the eye, thyroid, and pancreas (95–98). 
The absence of LTi cells, in a CXCL13 transgenic model, leads to 
the development of smaller and less organized infiltrates suggest-
ing a specific role for those cells in developing larger and more 
complex infiltrates (63). However, because the aggregates in these 
TABLe 1 | Markers associated with fibroblasts found in tertiary lymphoid structures observed in disease settings in mice and human.
Disease Mouse Human Reference
Sjögren’s syndrome  
(salivary glands and lacrimal glands)
Podoplanin/gp38, CD21, CXCL13,  
CCL21, VCAM-1, ICAM-1, ER-TR7, FAP
Podoplanin/gp38, CD21, Collagen I, Laminin,  
CXCL13, CCL21, CXCL12, BAFF, VCAM-1,  
ICAM-1, ER-TR7, FAP
(63, 66–69)
Primary biliary cirrhosis, primary  
sclerosis cholangitis (liver) 
n.d. Podoplanin/gp38, CD21, Collagen I, Laminin,  
CCL21, MadCAM-1
(63, 70, 71)
Rheumatoid arthritis (joints) Podoplanin/gp38, VCAM-1, CXCL13,  
CCL21, FAP, Thy1.1, Cadherin-11




Atherosclerosis (arteries) Podoplanin/gp38, VCAM-1, ER-TR7,  
LTβR, αSMA, CD35, CXCL13, CCL21
n.d. (76–79)
Autoimmune encephalitis/ 
multiple sclerosis (central nervous system)
Podoplanin/gp38, PDGFRα, PDGFRβ,  
VCAM-1, ICAM-1, ER-TR7, Fibronectin, 
Thy1.1, Cadherin-11
CXCL13, BAFF (64, 80)
Inflammatory bowel diseases (colon and 
small intestine)
VCAM-1, ICAM-1, CXCL13, CCL21,  
CXCL12, CD21/35, Podoplanin/gp38,  
ER-TR7
Podoplanin/gp38, CXCL13, αSMA, FAP, CD21 (81–85)
Mucosal-associated lymphoid tissue  
(MALT) lymphoma 
n.d. Podoplanin/gp38, CXCL13, CCL21, CXCL12 (67, 86)
Helicobacter pylori gastritis (stomach) FDC-M1 CD21, CXCL13, CCL21 (86–88)
Inducible bronchus-associated  
lymphoid tissue (iBALT) (lungs)
CD21/35, FDC-M1, CXCL13, CXCL12, 
CCL21, CCL19, CD90, Podoplanin/gp38
CD21, CXCL13, CCL21, CCL19, αSMA (89–92)
Diabetes (pancreas) Podoplanin/gp38, FDC-M1, CXCL13,  
CCL19, CCL21, CXCL12, BAFF
n.d. (63, 93, 94)
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models develop perinatally and in the absence of inflammation, 
this model cannot be considered a classical model of TLS, and 
conclusions on its elements should be carefully drawn.
The hierarchy of requirement of TNF family members in 
physiological lymphoneogenesis is clear, with LTα−/− mice 
lacking both LTα3 and LTα1β2 expression showing the most 
severe phenotype, characterized by lack of all LNs and PPs, and 
a disorganized splenic white pulps (99, 100). In contrast, LTβ−/− 
mice, which specifically lack LTα1β2 function, retain MLNs and 
cervical LNs, and their splenic defects are less pronounced than 
those of LTα−/− mice (101, 102). A similar phenotype is observed 
in pregnant mice treated with LTβR–Ig fusion protein, whose 
progeny lack most PLNs and PP but retain MLNs (103–105). 
Ruddle and her group have clearly shown that ectopic expression 
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of either TNFα, LTα, or LTα1β2 regulates the assembly of organ-
ized TLS, with the formation of MAdCAM+ (in LTα transgenic) 
and PNAd+ HEV (in LTα1β2 transgenic mice) and a complex 
network of lymphoid tissue chemokine expression (58, 106). In 
general, the combined expression of both LTα and β goes along 
with the formation of better organized lymphoid structures (58).
In spontaneous models of TLS formation, LTα1β2 is not 
absolutely required to prime the stromal cell compartment. 
Accordingly, the upregulation of adhesion molecules and the 
transient expression of lymphoid chemokines can occur in 
the absence of LTα1β2, or LTi and lymphocytes. Peduto and 
colleagues first demonstrated that a population of αSMA+ podo-
planin+ fibroblasts, which express lymphoid chemokines and 
survival factors, classically associated with lymphoid stroma in 
SLOs, can differentiate in non-lymphoid tissue during inflamma-
tion and cancer. This phenomenon occurs prior to lymphocyte 
infiltration in the tissue and is conserved in RORγ-deficient mice 
(27). Other leukocytes, which are more abundant in the earliest 
phases of inflammation, such as myeloid cells or granulocytes, 
might therefore assume a “initiator role” in the formation of TLS 
by releasing proinflammatory cytokines capable of inducing 
activation of resident fibroblasts (27, 69, 107–109).
Since, by definition, TLS arise at sites of inflammation, it 
is virtually impossible to exclude the contribution of one or 
more of the TNF family members to the early phases of TLS 
formation. Engagement of TNFR on inflammatory or lymphoid 
tissue fibroblasts is known to upregulate chemokines, cytokines 
(including BAFF and IL-6), and adhesion molecules that largely 
define a primed stroma (110, 111). Moreover, TNF is known to 
upregulate the receptors for some of the inflammatory cytokines 
proposed to be involved in TLS establishment (112, 113). One 
may therefore put forward the hypothesis that the engagement of 
TNF is key prior to, or synergistically, with the expression of other 
proinflammatory cytokines to drive the initial priming of resident 
fibroblasts into functional LTo cells.
Other members of the TNF family have been implicated in 
lymphoneogenesis. Transgenic expression of LIGHT has been 
shown to induce TLS formation in models of melanoma and 
fibrosarcoma (114, 115) and to exacerbate disease in NOD mice 
(93). Overexpression of RANKL can also support the establish-
ment of lymphoid tissue characterized by stromal cell production 
of lymphoid chemokines and lymphocyte recruitment (116–118). 
However, the mechanism by which RANKL regulates TLS assem-
bly is not clear.
Besides TNF and LT family members, the types of cytokines 
involved in the first phase of stromal cell priming in TLS vary 
according to the tissues and types of responses (Figure 1). IL-6 
has been associated with the perivascular accumulation of B cells 
and mature plasma cells (119). In a model of subcutaneous tumor 
apoptosis, TGF-β has been demonstrated to induce CXCL13 
expression (120), while IL-5 expression has been associated with 
iBALT development and lung disease (121). IL-4 and IL-13 are 
known to stimulate, to different extents, the upregulation of adhe-
sion molecules and transient chemokine expression on fibroblasts 
(122). Finally, IL-4, IL-7, and to a lesser extent IL-15, are known 
to stimulate expression of LTα1β2 on naïve T lymphocytes that 
might lead to TLS formation [reviewed in Ref. (95, 123)].
A separate case needs to be made for cytokines belonging to the 
IL-23 family. IL-17 production by γδ T cells has been demonstrated 
to provide the trigger for priming of lung fibroblasts in iBALT 
(92). During EAE, the development of a PDGFRα+PDGFRβ+ 
podoplanin+CD31− stromal cell network has been shown to be 
dependent on both IL-17 and IL-22 (64). Within murine salivary 
glands IL-22, but not IL-17, was deemed a key requirement for 
stromal cell activation in TLS that form (69). IL-23 expression has 
been associated with TLS formation in a model of arthritis (124), 
and the transfer of Th17 cells is sufficient to induce TLS during 
central nervous system tissue inflammation (109). Interestingly, 
the production of these cytokines and their relative source 
appears to be linked to the presence of the transcription factor 
RORγ that is also required for development and function of ILC3, 
γδ T cells, and Th17 cells (125–130). Several factors, like IL-23, 
may act upstream of RORγ, with IL-17 being downstream (131), 
thus increasing the level of complexity of this system. In some 
settings, RORγ is deemed dispensable, such as in virus-induced 
salivary gland infection, where TLS formation and autoantibody 
generation strongly depend on IL-22 but not IL-17 or RORγ 
(69). In a model of airway damage and inflammation, it has been 
shown that IL-17A might regulate both the expression and the 
proinflammatory properties of IL-22 (132), thus suggesting the 
possibility that several cytokines can initiate TLS establishment 
and their relative contribution is likely to be influenced by the site 
of inflammation and etiological agent.
To date, only one cytokine, IL-27, has been identified that 
directly inhibits TLS development by negatively regulating the 
differentiation of Th17 cells, a major driver of TLS development 
and RA pathogenesis (133).
In summary, multiple pathways and several cell types can act 
as initiators of TLS assembly and induce activation or priming 
of the resident fibroblasts in a way that leads to a lymphocyte 
permissive tissue state (Figure  1). The capacity of leukocytes, 
other than T and B cells, to provide cytokines for stromal cell 
activation demonstrates a critical uncoupling between stromal 
cell priming and lymphocyte accumulation in TLS, establishing 
a model whereby stromal cell priming might occur prior and 
largely independently from a significant lymphocyte migration 
into the tissue.
MATURATiON AND STABiLiZATiON OF 
FiBROBLASTiC STROMAL CeLLS 
ALLOwiNG TLS FORMATiON
Transient activation of stromal cells that often occurs in acute 
phases of inflammation is not sufficient to support complete 
lymphoid-like fibroblast maturation associated with TLS for-
mation. Upon resolution of inflammation, the “primed state” 
of fibroblasts is likely to be lost; alternatively, these activated 
cells may disappear. Only selected circumstances, such as 
antigen persistence or severity and length of the inflammatory 
response, may drive the development of lymphoid tissue-like 
mesenchyme. Part of this complex phenomenon is also reliant 
on the dramatic changes that both stromal cells and leuko-
cytes induce in the lymphatic and blood vasculature and that 
FiGURe 1 | Development and maturation of lymphoid tissue-like stromal fibroblasts in tertiary lymphoid structure (TLS). Multistep model illustrating the 
priming followed by the stabilization and maturation of the fibroblasts allowing a lymphoid tissue-like organization and function of the lymphocyte infiltrate. Acute 
inflammation within a tissue results in the localized production of several different proinflammatory cytokines by infiltrating leukocyte populations (initiators) and 
tissue-resident cells. These signals elicit “priming” of local stromal fibroblasts, which may include the upregulation of gp38, adhesion molecules, and inflammatory 
cytokines. Prolonged inflammation can lead to local production of LTα1β2, along with TNFα and LTα by hematopoietic inducer cells. This triggers changes in the 
stromal fibroblast phenotype and function, including the production of chemokines typically expressed in lymphoid organs. FDC differentiation from local fibroblasts 
might only occur at this stage, when a critical mass of LTα3/LTα1β2/TNFα signals are provided by the co-localizing B cells, possibly inducing a positive feedback 
loop. Organization of the resident stroma and hematopoietic cells in a T cell (blue cells) and B cell (green cells) rich zone enables priming and activation of T and B 
cells toward locally displayed antigens. The formation of GC supports affinity maturation and expansion of B cells clones and plasma cells. Not Illustrated: the 
presence and differentiation of the vascular network [reviewed in Ref. (57)].
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occurs as an integral part TLS development (57, 134). In this 
context, the ability of TLS-associated fibroblasts to secrete pro-
angiogenic factors, including VEGF-C and VEGF-D, should 
also be highlighted (27).
Interestingly, this two-step process of mesenchymal cell 
priming and maturation is reminiscent of the early phases in the 
process of lymphoid neogenesis, whereby the early production of 
CXCL13 and the upregulation of ICAM-1 and VCAM-1 on local 
mesenchymal cells occur independently of lymphotoxin and LTi. 
In SLOs, this first phase is followed by the LTα1β2-dependent 
interaction of LTi cells with the primed mesenchymal cells 
leading to their specialization as LTo cells capable of inducing 
HEV development, lymphocyte recruitment, and stromal cell 
specialization in various subsets (28, 29, 135). Interestingly, in 
SLOs, the resident mesenchyme is unable to maintain the durable 
production of survival factors and chemokines if TNFR or LTβR 
engagement is missing and only a few disorganized LN form 
in LTα−/− or LTβR−/− mice (38, 50). Accordingly, the prolonged 
treatment of adult wild-type mice with LTβR-Fc leads to dedif-
ferentiation of FDC, HEV, and partially fibroblastic reticular cells 
(FRC), and as a consequence to reduced lymphocyte recruitment, 
retention, and compartmentalization (136).
Similarly, in TLS, full differentiation of the lymphoid tissue-
like fibroblasts also requires the presence of lymphocytes and 
LTβR signaling. TLS can form in LTα−/− mice but display a 
disorganized pattern of lymphocyte aggregation, in absence of 
clear B/T cell segregation or HEV differentiation (90). LTβR-Fc 
treatment of established TLS leads to the same outcome, sug-
gesting a continuous need for these signals in order to main-
tain differentiated HEV and chemokine-expressing fibroblast 
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networks  (95, 137, 138). Continuous LTβR and TNFR1 sign-
aling is also required for sustained expression of VCAM-1, 
CXCL13, and CCL21 in TLS that form in the aorta and in the 
brain (64, 76, 77). This finding is reminiscent of the require-
ment for LTα2β1 in order to maintain normal numbers and 
compartmentalization of lymphocytes in the spleen, PP, and 
ILFs (47, 53, 137, 139, 140). The combined activation of TNFRI 
and LTβR is required for the formation of TLS in both inducible 
and spontaneous models of atherosclerosis (76, 77). However, 
blockade of LTβR is sufficient to reduce insulitis and diabetes 
(138) in a NOD mouse model characterized by the presence of 
podoplanin+ FRC networks and HEV differentiation (63).
All together, these data are consistent with a model of TLS for-
mation in which there is an initial phase of stromal cell priming 
that occurs independently of LT and precedes tissue infiltration 
by adaptive immune cells. In the second step, the maturation of 
resident fibroblasts to a full LTo phenotype appears to be depend-
ent in most settings on LT and TNF, presumably needed to 
enable dual activation of the NF-κB cascade, with the alternative 
pathway being maintained over time. Of note, continuous and 
strong expression of TNF and possibly other NF-kB activating 
cytokines may bypass this LTα1β2 requirement and still lead to 
TLS development, though the precise mechanism by which this 
phenomenon occurs has not been fully clarified. In the context of 
ectopic lymphoneogenesis, one may therefore propose an exten-
sion of the term “lymphoid tissue inducer” to different leukocyte 
cell types that express sufficient levels of LTα1β2 to induce full 
differentiation of resident mesenchymal cells into a lymphoid 
tissue phenotype (96, 108, 141–145). Naïve B cells and DC may 
qualify for this term, as these cell types on a wild type but not 
on a LT-deficient background can induce formation of lymphoid 
tissue structures in vivo (47, 146). Evidence is less strong for a 
LTi like role for T cells although they can express LTα1β2 upon 
cytokine exposure or activation (147).
Downstream the activation of LTβ receptor is the production 
of lymphoid tissue chemokines, critically required for lymphocyte 
recruitment and TLS development. Accordingly, ectopic CCL19 
expression under the rat-insulin promoter alone is able to form 
small infiltrates rich in T cells and dendritic cells; while ectopic 
CCL21 expression is able to induce the formation of large and 
better organized infiltrates, characterized by the specific develop-
ment of T and B zone stroma and HEV differentiation. Similarly, 
ectopic CXCL13 expression is known to regulate lymphoid tissue 
neogenesis with T and B cell segregation and complete specializa-
tion of the stromal compartment, including FDCs and HEVs (63, 
137). These findings in TLS formation are in keeping with the 
critical role played by CXCL13 and CCL21 in lymphoid organ 
development during embryogenesis (95).
Interestingly, different functional phenotypes, in terms of 
chemokine expression, have been observed in fibroblasts isolated 
from different anatomical sites. In the skin, podoplanin+ inflamed 
fibroblasts express modest levels of IL-7 and CXCL13, but high 
quantities of CXCL12 and VEGF-C (27). In contrast, podoplanin+ 
cells isolated from gut and tumors significantly upregulate the 
lymphoid chemokines CXCL13, CCL19, CXCL12, and various 
cytokines, including VEGF-C, connective tissue growth factors, 
including fibroblast growth factors (27). Stromal cells isolated 
from iBALT are characterized by CXCL12 expression (92), while 
the network of podoplanin+ CD31− cells isolated from salivary 
gland TLS express CXCL13 and CCL19 but not CXCL12 (69). 
Differences in terms of TLS organization and chemokine expres-
sion can also be observed at different sites or even in TLS at 
the same anatomical site when they are induced in response to 
different antigens. For example, intranasal administration of the 
poxvirus modified vaccinia virus Ankara (MVA) in mice is able 
to induce highly organized iBALT with B cell follicles containing 
a network of CXCL13-expressing FDCs and CXCL12-producing 
follicular stromal cells. However, mice treated with P. aeruginosa 
developed iBALT with B cell follicles that consisted of CXCL12+ 
follicular stromal cells but not CXCL13+ FDC (92). The signals 
responsible for these phenotypic and functional differences are 
unclear and most likely result from an integrated response to 
different anatomical environments, antigenic stimulations, and 
inflammatory milieus. While this review focuses on fibroblasts, 
the ability of hematopoietic cells, including macrophages, den-
dritic cells, and Th17 cells, to ectopically express CXCL13 should 
also be acknowledged, suggesting the possibility to consider the 
cytokine/chemokine, rather than its cellular origin as a therapeu-
tic target (148–152).
STROMAL FiBROBLAST ORGANiZATiON 
iN SLOs AND TLSs
Mature SLOs are characterized by the anatomical organization 
of lymphocytes in distinct compartments, which is due to the 
segregated chemokine expression of CCL19/21 in T zones and 
CXCL13 in B zones. The source of these chemokines are special-
ized subsets of resident FRC and FDC, which attract and retain 
specific leukocyte populations, besides providing survival factors.
Fibroblastic reticular cell subsets, including FDC, are defined 
by their phenotype, anatomical location, and function (2, 24, 
153, 154) (Figure  2). T zone FRCs or TRC classically inhabit 
the T cell cortex in LNs and are characterized by the expression 
of podoplanin and lack of the vascular marker CD31. TRCs are 
responsible for the recruitment, retention, and movement of 
naïve T lymphocytes and DCs via their expression of CCL19 
and CCL21. Besides regulating immune cell trafficking, TRCs 
produce extracellular matrix, forming a system of microchannels 
(conduits) that connect the subcapsular sinus with the paracortex 
and HEVs. TRCs also provide a significant source of IL-7, which 
in combination with CCL19, sustains naïve T cell survival within 
the LN T zone, regulating T cell homeostasis (22, 155).
Fibroblastic reticular cells that inhabit the outer B zone, 
also termed B cell zone FRCs (BRC), are characterized by high 
levels of BP-3 and podoplanin expression but lack FDC markers 
like CD21/35. BRC represent an important source of oxysterol 
chemoattractants, BAFF, CXCL13, and the Notch ligand DL4 
(156–158). Marginal reticular cells (MRCs) represent another 
B zone FRC population that sits underneath the subcapsular 
sinus and is characterized by RANKL and CXCL13 expression 
(35, 159). BRC and possibly MRC form conduit networks able to 
deliver lymph-drained information, including antigens, from the 
subcapsular sinus to the B cell area and eventually to the FDCs 
present within the B cell follicles (2, 153, 156–162). Due to their 
FiGURe 2 | Stromal fibroblast populations in SLO and TLS. (A) Fibroblast populations in the lymph node control the organization and survival of lymphocytes in 
distinct areas. Fibroblastic reticular cells (FRC) produce CCL19 and CCL21 along with the survival factor IL-7 to attract and maintain T cell populations and provide a 
niche in which their interaction with dendritic cells (DC) can occur. Follicular dendritic cells (FDC) produce CXCL13, which attracts CXCR5+ cells to the B cell follicles. 
Other stromal cells are thought to play a role during the germinal center reaction (i.e., CRCs) or in antigen delivery (MRC). (B) Mature TLS are characterized by 
segregation into distinct T cell and B cell areas including the presence of germinal center like structures and areas rich in plasma cells. Stromal cell populations that 
perform comparable functions to those found within SLO can be identified, which underlie this T/B cell segregation within the larger TLS.
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phenotypic similarities, MRCs were proposed to represent the 
adult equivalent of embryonic LTo cells (159). In support of this 
concept, MRCs were shown to be the precursors of LN FDCs 
during immune reactions (162).
Follicular dendritic cells are the prominent stromal cell subset 
found within the central part of primary B cell follicles and local-
ize specifically to the light zone of the GCs in secondary follicles. 
FDCs are defined by their dendritic appearance and their capacity 
to retain opsonized antigen via Fc and complement receptors. 
FDCs serve as long-term reservoir of native antigen for the 
positive selection of affinity matured GC B cells or centrocytes 
(163). In addition, FDCs are a source of CXCL13 and BAFF, 
responsible for migration and survival of naïve B cells. TNFR and 
LTβR signaling are critically required for the maintenance of the 
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FDC network and in general to support the CXCL13 producing 
stroma in the follicles (53, 164, 165), as evidenced by their rapid 
disappearance upon TNFR or LT blockade (45, 166–169).
Recently, a population of CXCL12-expressing reticular cells 
(CRCs) has been described in the dark zone of the primary fol-
licles and polarized GCs, where they are required for the recruit-
ment of CXCR4+ centroblasts and effective GC responses (170). 
This subset is fate mapped by both the Cd21-cre and Ccl19-cre 
mouse lines with the fate mapping indicating past and/or present 
expression (171). It lacks most of the classical markers of FDCs 
[such as CD21/35, VCAM-1, FDC-M2, FDC-M1, M-2, and 
CD16/32 (FcγRII/III)] or FRCs (such as laminin and type IV 
collagen association). Moreover, CXCL12 expression on CRCs is 
independent of LT or TNFα thus establishing critical phenotypic 
and developmental differences between CRC and FDCs (171). 
Finally, a population of versatile stromal cells (VSC) has been 
described at the T zone edges of the B cells follicle, able to respond 
to inflammatory stimuli, B cell contact, and LTα1β2 stimulation 
by upregulating CXCL13 expression (172).
Many of the FRC subtypes are fate mapped by the same 
Ccl19-Cre transgenic mouse, suggesting a common precursor in 
embryonic life for the majority of FRC subsets, at least in the LN 
(171). In future, mice allowing inducible fate mapping are needed 
to gather more direct evidence for such a precursor–progeny 
relationship, both in embryonic and postnatal LN. Currently, 
very little is known on the specific differentiation and survival 
signals leading to the complex stromal cell organization observed 
in adult life.
To study signals regulating FRC function, various FRC lines 
have been generated from adult murine and human SLO. Murine 
cell lines constitutively produce CXCL12 and sometimes BAFF 
but require stimulation of the TNF receptor to upregulate various 
inflammatory chemokines (e.g., CXCL10, CCL4/5) as well as IL-7 
(33, 35). Stimulation of LTβ- or TNF-receptors strongly upregu-
lates matrix production, with the combination of both signals 
showing synergistic effects. Those signals could be mimicked by 
CD4+ T cells, physiological neighbors of FRC in vivo. Similarly, 
stimulation of a MAdCAM+ MRC line via both LTβ- and TNF-
receptors was also able to induce further expression of CXCL13 
and CCL19 (33, 35). Interestingly, fluid flow was shown able to 
induce CCL21 expression in a FRC line (173); while human LN 
FRC responded to TNFα, IL-6, IL-4, and IL-13 by upregulating 
various cytokines, adhesion molecules, and metalloproteinases 
(174). These in vitro data support an ability of lymphoid tissue 
fibroblasts to adopt different functions depending on the signals 
received from the surrounding environment, and thereby influ-
ence neighboring immune or stromal cells.
Our knowledge about stromal fibroblasts within murine and 
human TLS is still very limited. Current evidence suggests the 
presence of TRC-like cells within the T cell rich zones, and of 
FDC-like cells that inhabit B cell rich areas in more organized 
TLS. MRCs, BRCs, CRCs, or VSCs have not yet been described 
in TLS. Depending on the size and type of TLS, fibroblasts dis-
play a variable degree of the phenotypic and functional features 
described for their SLO counterparts (Figure 2). It is debatable 
the extent to which TLS stroma reaches a comparable level of 
polarization and differentiation compared to SLO stroma. The 
two subsets identified so far in TLS, namely CCL21+ TRC and 
CXCL13+ FDC, can associate and probably form distinct com-
partments, such as T and B zones but also allow the formation 
of functional conduits and GCs (63). These niches appear to be 
functional in generating a specific adaptive immune response, 
but it is less clear whether fibroblasts in TLS allow a compa-
rable regulation of immune processes. It is likely that in TLS, 
similar to SLOs, the predominant lymphocytic population that 
accumulate in each area imprint locally activated mesenchyme 
to support an increased requirement for specific survival and 
chemo-attractive factors. Lymphoid stromal cell differentiation 
would therefore be programed by anatomical location through 
contact with neighboring cells. Any polarization toward an FRC-
like or FDC-like phenotype may be reenforced as lymphocyte 
segregation arises within mature TLS by the expression of one 
or two chemokines, such as CXCL13 and CCL21 (61, 66, 67, 
72), thereby restricting stromal cell contact to either T or B cells. 
It is known that both CXCL13 and CCL21 can induce LTα1β2 
expression in the responding lymphocytes, further enhancing 
chemokine expression by the neighboring fibroblasts (95, 142). 
The additional factors needed besides LTα1β2 to drive fibroblasts 
into a differentiation program specific for the B zone or the T zone 
are currently unknown.
In murine TLS, TRC-like cells expressing podoplanin and 
other markers (Figure 2; Table 1) are found throughout T cell 
rich zones as three-dimensional reticular networks and partly 
co-localize with dendritic cells thereby forming an environment 
where cognate T cell stimulation is possible. They associate with 
matrix fibers that can form functional conduits and connect with 
HEVs. Often they express CCL21, which is key to the T zone 
formation. CCL19 and IL-7 expressed by FRC may contribute to 
local T cell accumulation and possibly to random T cell migration 
along the TRC network (2, 153, 155, 175).
Follicular dendritic cell networks form only within B zones of 
large TLSs in mice and are then associated with functional GCs 
allowing B cell differentiation to affinity matured plasma cells 
(63, 88, 92, 94, 176, 177). Interestingly, not all tissues, and only 
a minority of TLSs form fully mature FDC networks, suggesting 
that while the stimulus for FDC differentiation might be the same 
as that observed in SLO (TNFα and LT), the threshold required 
for full FDC differentiation in peripheral tissue is higher. An 
alternative possibility is that FDC precursors in the periphery are 
scarce and differentially distributed in different organs. Whether 
the phenotype, origin, and function of FDCs in peripheral TLSs 
differ from those of SLO is not known, neither is their differential 
dependency on LT or LT-inducing pathways. It is important to 
highlight that even in SLOs, at least two different precursors have 
been identified for FDCs, which differ between spleen and LNs 
(162, 178, 179), thus potentially increasing the complexity of 
signals and progenitors required for FDC differentiation in TLS.
While it is likely that in TLS a single lymphoid tissue-like 
progenitor gives rise to both FRC and FDC-like cells, it cannot 
be excluded that FDC might differentiate from FRC-like cells or 
another precursor later in TLS development. Interestingly, the 
absence of MRC-like cells and the lack of any anatomical capsule 
within the TLS appears to exclude the involvement of an “MRC-
like progenitor” in FDC differentiation in TLS. Data obtained 
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from parabiosis experiments and fate mapping experiments by 
Peduto and colleagues suggest that local, rather than circulat-
ing, precursors are responsible for the expansion of the stromal 
network responsible for TLS establishment (27). Proliferation 
of the resident stroma has been also observed in an inducible 
model of TLS, both in the vascular and stromal compartments 
(134) (Nayar et  al., manuscript in preparation), which mimics 
the expansion of the stromal compartment during immunization 
in SLOs (22, 180–182). Therefore, the most likely scenario is that 
local differentiation and expansion of tissue-resident mesenchy-
mal cell/s accounts for TLS development.
Even less is known about fibroblasts found in TLS within 
human pathology, in part due to the lack of markers identifying 
fibroblasts and distinguishing different cell subsets. Most efforts 
have concentrated on reporting the presence or absence of CD21+ 
FDCs or lymphoid tissue chemokines, such as CXCL13, CCL21, 
CCL19, and CXCL12 (7, 8, 183). Discrete expression of CXCL13, 
CXCL12, and CCL21 has been described in salivary glands of 
patients with SS, RA, multiple sclerosis, primary sclerosing 
cholangitis, atherosclerosis, inflammatory bowel disease, chronic 
lung diseases, Helicobacter pylori-induced gastritis, and lym-
phoma [reviewed in Ref. (7)]. However, this classical work largely 
preceded the phenotypic characterization of fibroblast subsets in 
mice and therefore lacks in-depth characterization of the stromal 
cell compartment. Nonetheless, the association between the level 
of organization of TLS with lymphoid chemokine expression (7), 
together with identification of the source of lymphoid chemokines 
in the αSMA+ or desmin+ stromal compartment (63), suggests 
that TLS fibroblast subsets exist in humans. More recently, our 
laboratories have demonstrated the presence of podoplanin+ 
FRC-like cells in tonsil, RA synovium, and SS salivary glands, 
as based on the expression of podoplanin and CCL21 and the 
association with T cells, DC, and matrix fibers (63). These FRC-
like cells were distinct from the CD21+ FDC that organized B cell 
rich zones, as described previously by several laboratories and 
summarized in Table 1.
While the use of podoplanin to identify “lymphoid tissue 
stromal cells” in the periphery remains a reasonable approach, 
podoplanin expression has also been observed on epithelium, 
lymphatic vessels, Th17 cells, and myeloid cells (184). Its use 
therefore requires careful analysis of cell morphology and double 
labeling with cellular markers (absent on fibroblasts) to validate 
the specificity of the population of cells detected. In future, it 
will be important to use further markers to discriminate human 
fibroblast subsets in TLS, in order to improve stromal cell char-
acterization in human TLS histology samples.
eFFeCTOR FUNCTiONS OF TLS
Tertiary lymphoid structures are classically defined as lymphoid 
aggregates forming in organs whose main function is other than 
the initiation of an adaptive immune response. TLS appear to 
form there because of an abundance of antigen, either “self ” 
in autoimmune diseases, “self ” or “altered self ” in cancer, or 
foreign antigen/s during infections and transplant rejection. At 
those ectopic sites, TLS can contribute to the generation of an 
antigen-specific immune response with plasma cell and antibody 
generation, often maintained by the persistence of the antigen 
and/or inflammatory signals (6, 8). The local stromal structures 
needed for naïve cell recruitment and affinity maturation of the 
B cell compartment are mainly observed in the most organized 
TLS (66, 185). Interestingly, TLS do not develop in all forms of 
chronic inflammation and only arise in certain permissive tis-
sues. A classical association with mucosal epithelium has been 
observed. However, TLS can form in the synovium, a tissue 
devoid of epithelial structures (7). The factors involved in tissue 
permissiveness are not clear, and while it is intuitive to suggest the 
need for proximity to antigen and antigen presenting cells, this 
is not sufficient as exemplified by the case of the skin, classically 
considered a “hostile site” for TLS formation.
Aggregation of lymphocytes in small TLS is commonly 
observed in transient infections where it is considered a positive 
development, aimed at containing local infections. The develop-
ment of lung TLS in response to influenza supports the further 
development of a strong antigen-driven T cell response contrib-
uting to viral clearance (186, 187). In these cases, TLS disappear 
shortly after pathogen clearance leaving the tissue intact (68, 188).
However, in chronic inflammation, the presence of TLS has 
been associated with poor clinical outcome and disease progres-
sion rather than resolution (94, 189). TLS formation correlates 
with serum autoantibody levels, disease severity, tissue damage, 
and decreased organ function in several diseases including SS 
[reviewed in Ref. (7)]. In RA, the formation of subchondral bone 
TLS supports osteoclast activation and tissue damage (190), and 
the presence of synovial TLS associates with anti citrullinated 
antibody production and poor response to anti-TNF antibodies 
(74, 191). Accordingly, levels of TLS-associated CXCL13 expres-
sion correlates with disease severity and persistence of subclinical 
synovitis (190, 192, 193).
It is arguable that TLS represent a response to and are not 
per se a cause of inflammation. However, a combination of fac-
tors, among which excessive cell recruitment, poor lymphatic 
drainage, disorganized cellular interaction, and excessive survival 
factors can contribute to TLS persistence in tissue, favoring a 
pathogenic role in the context of diseases. Interestingly, not all 
patients with autoimmune disease develop TLS, despite the pres-
ence of factors associated with its development, for example, Th17 
cells in RA (133). This suggests that the biological relationship 
between disease progression, clinical features, and TLS forma-
tion is more complex. In this context, the detection of GC within 
salivary glands of patients with SS has been classically associated 
with increased risk of lymphoma (194), suggesting that chronic 
antigen stimulation and excess of survival factors might favor the 
development of malignant B cell clones. However, this proposal 
is controversial and a strong positive correlation between the two 
pathogenic entities cannot be identified, leaving the relationship 
between TLS formation and lymphoma development uncertain 
(194, 195).
The role of TLS in the context of cancerous growth is also 
debated. TLS are believed to sustain the antitumor response in 
solid malignancies that arise in the colon, breast and ovaries as 
the presence of TLS in the context of cancer has been associated 
with a favorable prognosis (196). Nonetheless the ability of 
tumor cells to induce T regulatory cells (Treg) and suppress the 
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host immune response is well known and there is the possibility 
that cancer cells highjack TLS to exert this immunosuppressive 
function (197–200).
Classically, the key effector function associated with TLS 
development has been the formation of GCs and the produc-
tion of autoantibodies [reviewed in Ref. (7)]. However, more 
recently a more complex role for TLS in the context of T cell 
activation and maturation of pathogenic T cell response has 
been proposed.
While the production of CXCL13 represents a sensitive 
and powerful readout of stromal cell activation in TLS (69), 
this is unlikely, in the early phases of TLS establishment, to 
be restricted to the rather complex events of follicular B cell 
differentiation, an event that occurs later in TLS (69). It is likely 
that early CXCL13 production in the context of TLS assembly 
is aimed at driving the recruitment of CXCR5+ B cells and 
T  follicular helper (Tfh) cells (201). Accordingly, interfering 
with Tfh infiltration by ICOS-L blockade results in reduced TLS 
assembly and progression of vascular disease in a model of TLS 
associated with atherosclerosis (202). The origin of Tfh that arise 
within TLS is currently not clear. As mentioned, Tfh populations 
have been identified within the circulation in both mice and 
humans that could be recruited into TLS by newly established 
CXCL13 gradients (203–205). There is however the possibility 
that TLS provide a site for local Tfh differentiation. In support to 
this hypothesis, naïve T cell recruitment and priming has been 
reported within TLS that form in pancreatic tissue in NOD mice 
(93). However, naïve T cell recruitment requires the upregula-
tion of CCR7 and L-selectin ligands on the vascular endothe-
lium, typically HEVs (59, 206), which is another hallmark of 
mature TLS. Effector T cells are more likely to be recruited in the 
earliest phases of TLS assembly, thus suggesting that in TLS, as 
opposed to SLO, T cell differentiation into Tfh might occur from 
previously activated peripheral T cell populations that already 
display effector functions. In support of this hypothesis, Th17 
cells isolated from TLS of EAE affected mice display features of 
Tfh, including the upregulation of expression of CXCR5, ICOS 
and Bcl6 (109). Within TLS the activated fibroblast compart-
ment may provide key signals for T cell differentiation, such 
as IL-6, required for the induction and maintenance of the Tfh 
phenotype (207, 208), thus suggesting an additional role for 
stromal cells in the context of TLS development.
The presence and function of Treg populations in the context of 
TLS has been less studied. Treg recruitment into TLS might directly 
interfere with the activity of TLS associated Tfh cells, similarly to 
what has been described in SLOs (209, 210). Accordingly, in TLS 
that form in association with atherosclerosis, disruption of CD8+ 
Treg activity is known to induce an expanded GC B cell response 
(202). Additionally, in a mouse model of lung adenocarcinoma, Treg 
that inhabit local TLS, are known to interfere with the antitumor 
T cell response. In addition to directly inhibiting T cell responses 
within the TLS, Treg appear to impact upon the recruitment of 
additional lymphocytes to the TLS by affecting the formation or 
maintenance of PNAd+ HEVs (211, 212). Interestingly, the tumor 
microenvironment is conducive to the recruitment, generation, 
and maintenance of Treg populations (197) and, indeed, Treg 
infiltration in solid tumors is considered a negative prognostic 
factor. Whether Treg are less active or abundant in TLS associated 
with chronic inflammation, as compared to cancer, remains to 
be answered.
T regulatory and Th17 cell differentiation is promoted by TGF-
β; however, Th17 development occurs on a background of proin-
flammatory cytokines, such IL-6, IL-21, and IL-23 (213–215). It 
is possible that in TLS that arise in chronic autoimmunity, the 
inflammatory milieu, partly established by locally activated fibro-
blasts, positively enforce Th17 over Treg differentiation, favoring 
the upregulation of the transcription factor RORγ while inhibiting 
FoxP3 expression (216). Additionally, an environment that is rich 
in IL-1 and IL-6 and deficient in TGFβ is sufficient to reprogram 
Treg toward a Th17 phenotype (217, 218), thus suggesting that the 
inflammatory microenvironment associated with TLS in chronic 
inflammation may not be able to maintain Treg phenotype cells. 
Indeed, Th17 differentiation has been observed in RA TLS (133). 
The differences between diverse T effector populations and the 
balance between T effector and Treg cells in the different lymphoid 
niches may therefore explain some of the discrepancies observed 
between immune responses that occur within TLS associated 
with cancer and chronic inflammation.
It is not clear to what extent the stromal cell compartment 
contributes to TLS pathogenicity. In SLOs, FRC are increasingly 
recognized as active modulators of the immune response. FRCs 
can interfere with the T cell response through several mecha-
nisms, releasing soluble modulators that negatively regulate 
T  cell proliferation or providing negative co-stimulatory mol-
ecules such as PD-L1 (219–221). The ability of FRC to acquire 
peptide–major histocompatibility (MHC) II complexes from 
professional antigen presenting cells or to upregulate MHC I 
and II molecules has also been shown. Moreover, FRC are able 
to display peripheral tissue antigens mediating the deletion of 
peripheral autoreactive CD8+ T cells (19, 222, 223) and maintain-
ing the homeostasis of Treg cells (222, 224). Taken together, these 
studies demonstrate that, while FRCs provide survival niches for 
lymphocyte homeostasis, they also govern the magnitude of the 
immune response (19, 221).
The extent to which the regulation of immune responses 
by stromal cell populations translates from SLOs to TLS has 
not been explored. Interestingly, fibroblasts isolated from non-
inflamed peripheral tissues display a strong propensity to inhibit 
T cell responses, possibly to protect non-lymphoid tissues from 
the harmful effects of inflammation (221). In cancer-associated 
TLS, also characterized by a chronic inflammatory response, 
stromal fibroblasts are believed to contribute to immune eva-
sion, preventing lymphocyte effector functions and immune 
cell access to the cancer site (12). However, in contrast with 
these, most recent findings and the immunosuppressive role 
described for stromal cells in SLOs and cancer, current evidence 
strongly suggests a pathogenic role for TLS in autoimmune 
conditions, sustaining lymphocyte survival and supporting 
lymphocyte persistence in the tissue (7, 8). The pathogenic, 
non-immunosuppressive role of lymphoid-like fibroblasts that 
inhabit TLS found in chronic inflammatory conditions appears 
therefore unique and requires further characterization. There is 
the possibility that functional differences exist among fibroblasts 
that bear a similar phenotype in TLS and SLOs or that functional 
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differences are acquired during disease progression. The differ-
ent origin of SLO and TLS fibroblasts and the cytokine milieu 
driving mesenchymal differentiation at ectopic peripheral sites 
are likely to contribute to this complex phenomenon. A more 
detailed characterization of the stromal compartment in TLS 
associated with chronic inflammation in comparison with SLOs 
might provide key elements to unravel these discrepancies.
STROMAL FiBROBLAST DeLeTiON: 
A NOveL STRATeGY TO MANiPULATe 
THe iMMUNe ReSPONSe
Interesting insights into the function of SLO fibroblasts have 
been derived from cell deletion experiments. Taking advantage 
of the mouse lines expressing diphtheria toxin receptor (DTR) 
selectively in fibroblasts by the use of the fibroblast-specific 
promoters of FAP (fibroblast activation protein α) or CCL19, 
stromal cell deletion could be obtained in adult LNs. FAP–DTR 
mice treated with DTX showed disrupted LN homeostasis with 
strongly reduced numbers of T and B lymphocytes and DCs. 
Upon influenza infection, mice lacking FAP+ cells mounted a 
diminished immune response characterized by reduced num-
bers of GC B cells, plasma B cells, and Tfh cells (225). By using 
a different inducible transgenic model [Ccl19-Cre ×  Rosa26-
diphtheria toxin receptor (iDTR) mice] Turley, Ludewig, and 
colleagues demonstrated that selective depletion of FRCs 
resulted in aberrant localization of T lymphocytes within the 
LN cortex as well as a reduction in both CD4 and CD8 T cell 
numbers via a mechanism dependent on IL-7. Antigen-specific 
T cells isolated from these immunized, FRC depleted mice failed 
to undergo priming and proliferation (157, 226). Humoral 
responses and B cell homeostasis were also impaired in the 
absence of FRC, with disorganized B cell accumulation within 
the GCs and significant reduction of virus-specific antibody 
production (157). While this defect was largely attributed to 
the inability of B cells to access homeostatic levels of BAFF once 
FRC were depleted (157), Acton et  al. recently demonstrated 
that the engagement of CLEC-2 (expressed on DC) by its ligand 
podoplanin (expressed on FRC) is necessary for DCs to spread, 
migrate, and provide appropriate Ag presentation to T cells in 
LNs (227, 228). This suggests that the inability of the DCs to 
migrate into LNs in FRC-depleted LNs could contribute to the 
defect in T and B activation observed in this model. It has been 
reported that ablation of FDC achieved in Cd21-Cre × Rosa26-
iDTR mice results in loss of primary B cell follicles. This effect, 
partially mediated by BAFF and CXCL13 depletion, is also 
supported by the decreased levels of IL-6 and integrins present 
in SLO of transgenic mice treated with DTX (229). All together, 
these studies indicate that alterations in SLO stromal compart-
ments can alter lymphocyte survival, compartmentalization, 
and immunological competency, often sequentially linked, 
which profoundly impact on SLO function.
The impact of stromal cell deletion on TLS has not been 
addressed as yet and might provide critical clues on the relative 
immunosuppressive or proinflammatory role of TLS-associated 
stromal cells, ultimately unveiling whether the role of TLS in 
different diseases at various anatomic sites is beneficial or detri-
mental. Whether this approach, using antibody-based therapeu-
tic agents will be feasible in humans is of interest. Deletion of 
specific subsets of fibroblasts might be problematic due to the 
anatomical impact related to the apparent overlap of markers 
between lymphoid stroma in SLOs, TLSs, and non-lymphoid 
tissues. However, a series of compounds able to interfere with 
stromal cell activation and functions are available and will present 
an interesting avenue to target stromal cell activation, alone or 
in combination with current immunomodulatory agents, such as 
anti-TNFα, anti-IL-6, anti-CTLA4 and anti-PDL1.
CONCLUSiON
The main function of TLS is to maintain lymphocytes popula-
tions and provide a level of structural organization that enables 
the development and regulation of an adaptive immune response 
within peripheral tissues. This role is largely played by distinct 
populations of activated mesenchymal cells that acquire features 
similar to those of the lymphoid fibroblasts that inhabit SLOs. 
However, fibroblast maturation in TLS is an event, which is highly 
influenced by the anatomical site, the danger signals, and the 
inflammatory microenvironment, thus profoundly differing from 
the stereotypic mesenchyme specification observed during SLO 
development. Moreover, the organization and size of TLS does not 
equal that of their highly regulated SLO counterparts. The likely 
inability to precisely control leukocyte recirculation and cross 
talk within diseased tissue together with the absence of finely 
regulated chemokine gradients for lymphocyte positioning and 
the abundance of lymphocyte survival factors might explain why 
TLS fail to resolve and thereby contribute to immune-mediated 
inflammatory disease and its persistence.
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